Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation


SAN DIEGO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR). 

Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. 

On May 7, 2018, a lawsuit was filed against Esperion Therapeutics, Inc. over alleged securities laws violations. More specifically, the plaintiff claims that the defendants made false and/or misleading statements and/or failed to disclose that Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death, and that as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times. On October 22, 2018, an amended complaint was filed.  

Those who purchased Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares should contact the Shareholders Foundation, Inc.  

CONTACT:
Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
mail@shareholdersfoundation.com 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108 

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.